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Treatment
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PURPOSE. Corneal allograft rejection in rats can be prevented by subconjunctival injections of
liposomes containing dichloromethylene diphosphonate (clodronate–LIP), which selectively elim-
inate macrophages. In this study, the effect of clodronate–LIP treatment on cytokine mRNA levels
in corneal allografts was examined.
METHODS. AO rats received corneal grafts of PVG rats. Rats were either not treated or injected
subconjunctivally with clodronate–LIP on the day of transplantation and on postoperative days
(PODs) 2, 4, 6, and 8. RNA was isolated from the graft and rim of corneas at different times after
transplantation and from normal controls. Interleukin (IL)-1b, IL-1 receptor antagonist (IL-1RA),
IL-2, IL-4, IL-6, IL-10, IL-12p40, tumor necrosis factor (TNF)-a, TNF-b/lymphotoxin (LT), interferon
(IFN)-g, monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 2 (MIP-2)
mRNA levels were analyzed by semiquantitative reverse transcription–polymerase chain reaction
(RT–PCR).
RESULTS. Corneal rejection, observed in all untreated rats by POD 12, was associated with increased
mRNA levels of all cytokines investigated in grafts and rims. Clodronate–LIP treatment prevented
allograft rejection and strongly decreased the levels of IL-1b, IL-1RA, IL-2, IL-4, IL-6, IL-10, IFN-g,
TNF-b/LT, MCP-1, and MIP-2 mRNA in grafts and IL-1 b, IL-2, IL-4, IL-6, and IFN-g mRNA in rims.
Interleukin-12p40 mRNA levels were unaltered in clodronate-treated rats, except for a transient
increase in grafts at POD 3. TNF-a mRNA levels were increased by clodronate–LIP in grafts and rims
early after transplantation (PODs 3 and 7). Despite a normal appearance, long-term accepted
corneal grafts (POD 100) contained mRNA for IL-10, IL-12p40, TNF-a, MCP-1, and MIP-2.
CONCLUSIONS. Clodronate-liposome treatment markedly altered the mRNA levels of all cytokines
investigated in corneal allografts. These results may explain in part the mechanism by which
clodronate–LIP treatment prevents corneal allograft rejection. (Invest Ophthalmol Vis Sci. 1999;40:
3194–3201)
Despite advances in surgical techniques and immuno-suppressive drug treatment, allograft rejection still oc-curs in 10% to 30% of the cases of penetrating kerato-
plasty and is the major cause of corneal graft failure.1,2 Corneal
allograft rejection is characterized by infiltration of mainly T
cells and macrophages into the donor tissue.3,4 Depletion of
CD41 T cells by systemic administration of specific monoclo-
nal antibodies markedly reduced corneal graft rejection.5,6
Topical application of such anti-CD4 antibodies also reduced
allograft rejection.7 Using a technique to eliminate macro-
phages, we previously showed that these cells are also crucial
for the rejection process.4 Macrophages can be eliminated in a
selective manner, due to their phagocytic activity, by lipo-
somes containing the drug dichloromethylene diphosphonate
(clodronate–LIP).8 After uptake by macrophages, the phospho-
lipid bilayers of the liposomes are degraded by lysosomal phos-
pholipases and the released drug causes cell death.9 In our
study, five consecutive injections of clodronate–LIP into the
subconjunctiva of rats early after transplantation produced
100% survival of corneal allografts for up to 100 days. This
treatment was characterized by reduced cellular infiltration
and reduced neovascularization of the grafted cornea.4 Re-
cently, we found that clodronate–LIP prevented the induction
of cytotoxic T cells and cytolytic antibodies directed against
the donor tissue,10,11 which indicates that clodronate affects
antigen presentation.
Although the molecular mechanisms underlying corneal
graft rejection are still not completely understood, cytokines
released at the grafted site are thought to be involved in the
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attraction, activation, and proliferation of T cells and macro-
phages.12–14 Recently, we reported that corneal allograft rejec-
tion in rats was associated with increased mRNA levels of
multiple cytokines, including interleukin-1b (IL-1b), IL-1 recep-
tor antagonist (IL-1RA), IL-6, IL-10, tumor necrosis factor-a
(TNF-a), monocyte chemotactic protein 1 (MCP-1), and mac-
rophage inflammatory protein 2 (MIP-2), which were detected
immediately after transplantation and during rejection.12 The
expression of known T cell–derived cytokines, including IL-2,
IL-4, and interferon-g (IFN-g), was detected after rejection
occurred, underlining the central role of T cells in this process.
Recently, others have also demonstrated expression of IL-2 and
IFN-g during corneal allograft rejection in mice.13,14 These
results imply that cytokines contribute to corneal graft rejec-
tion. Expression of IL-1b, IL-1RA, IL-6, IL-10, MCP-1, and MIP-2
was also detected after transplantation of corneal autografts
that were not rejected,12 indicating that some of these factors
are already triggered by traumatic events alone.
In the present study we have expanded our analysis of
cytokine expression in corneal allografts. We examined cyto-
kine mRNA expression patterns in rejected corneal allografts
and in accepted allografts of rats treated subconjunctivally with
clodronate–LIP using semiquantitative reverse transcription–
polymerase chain reaction (RT–PCR). Our results show that
clodronate–LIP treatment markedly decreased the mRNA ex-




Inbred male AO and PVG rats (Harlan Sprague–Dawley, Bices-
ter, England), 10 to 12 weeks of age at the time of transplan-
tation, were used in this study. These strains differ in their
major histocompatibility complex (MHC) antigens.15 Rats were
treated according to the ARVO Statement on the Use of Ani-
mals in Ophthalmic and Vision Research and the guidelines of
the Animal Care and Ethics Committee of the Royal Nether-
lands Academy of Sciences. Rats were housed under standard
conditions and were given food and water ad libitum.
Corneal Surgery and Clinical Evaluation
Orthotopic corneal transplantations were performed on one
eye of AO rats as described earlier.4,12,16 Briefly, before corneal
surgery, maximal mydriasis was induced by subcutaneous (SC)
injection of atropine sulfate and topical atropine and phenyl-
ephrine drops, to prevent trauma to the iris and anterior
synechiae formation. A 3.0-mm diameter trephine was used to
mark both recipient and donor corneas and curved fine scis-
sors were used to remove the buttons. Donor corneas were
kept in corneal preservation medium (Eagle’s modified essen-
tial medium with 2% fetal calf serum, 100 IU/ml penicillin, and
100 mg/ml streptomycin) until use. The donor button was
sewn into the recipient cornea using eight stitches of a con-
tinuous 10–0 monofilament nylon suture. Sutures were left in
place for the duration of the experiments (up to POD 100).
Transplanted rats were examined using an operating mi-
croscope every other day until POD 17 and weekly until POD
100. Opacity and neovascularization of transplanted corneas
was graded using a scoring system described previously.4 Max-
imal opacity was graded 4, and maximal neovascularization
was graded 16 (score 4 for every quadrant of the cornea).
Corneal rejection was defined as a graft opacity score of 3 or
higher in a previously clear graft.
Liposome Preparation and Subconjunctival
Injections
Multilamellar liposomes, composed of phospholipid bilayers,
containing dichloromethylene diphosphonate (clodronate;
kindly provided by Boehringer Mannheim, Mannheim, Ger-
many) were prepared as described elsewhere.17 Clodronate–
LIP was suspended in phosphate-buffered saline and stored at
4°C until use. A total volume of 100 ml of clodronate–LIP was
injected into the subconjunctiva near the limbal area using a
50-ml Hamilton syringe with a 30-gauge needle. Four injections
of 25 ml each were given, in four different quadrants, to
produce a circular bleb.
Experimental Design
Rats with technical transplantation or liposome injection fail-
ures (5 in total) were excluded from the study. Rats with
successful corneal grafts (n 5 42) were divided into two
groups: control rats (n 5 20) that received no treatment. Of
this group, five rats each were killed on PODs 3, 7, 12, or 17 by
intravenous injection of a lethal dose of pentobarbital. Clodr-
onate–LIP–treated rats (n 5 22) that received subconjunctival
injections of liposomes at the time of corneal transplantation
and on PODs 2, 4, 6, and 8. Five rats each were killed on PODs
3, 7, 12, or 17 and two rats on POD 100. In addition, 4 AO rats
that did not undergo surgery were used as normal controls.
After termination, rats were perfused through the left
ventricle of the heart with 500 ml sterile pyrogen-free saline to
remove cells from blood vessels. Subsequently, the graft (i.e.,
the central corneal button) and the rim (i.e., the adjacent
peripheral ring) of the recipient cornea were removed, imme-
diately frozen in liquid nitrogen, and stored at 270°C until RNA
isolation.
RNA Isolation and cDNA Synthesis
Total RNA was isolated from all samples by a single-step ex-
traction method.18 Corneal tissues were homogenized by vig-
orously vortexing in RNAzol (Cinna Biotecx Laboratories,
Houston, TX), and the extracted RNA was dissolved in 10 ml
sterile water. For cDNA synthesis, 5 ml of total RNA was
incubated with 2.5 mg oligo(dT)12–18 primer, 10 mM dNTPs
(Pharmacia, Woerden, the Netherlands), and 200 U Superscript
RNaseH reverse transcriptase (GIBCO–BRL, Eggenstein, Ger-
many) according to the manufacturer’s instructions. After in-
cubation for 1 hour at 37°C, the reaction was terminated at
65°C for 5 minutes. cDNA was stored at 270°C until use.
PCR Primers and Internal Control Probes
The sense and anti-sense PCR primers and internal control
probes for b-actin, IL-1b, IL-1RA, IL-2, IL-4, IL-6, IL-10, IFN-g,
TNF-a, MCP-1, and MIP-2 have been described.12,19 Primers
and probes for the inducible p40 subunit of IL-12 (IL-12p40)
and TNF-b/lymphotoxin (LT) were designed using sequences
obtained from the GenBank database and are shown in Table 1.
PCR and Southern Blot Analysis
Semiquantitative PCR amplification and analysis of PCR prod-
ucts were performed as previously described.12,19 For PCR
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amplification, cDNA was added to a reaction mixture consist-
ing of 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100,
1.5 mM MgCl2, 0.2 mM dNTP, 0.2 mM sense and anti-sense
oligonucleotide primers, and 1 U Taq DNA polymerase (Pro-
mega, Madison, WI) in a volume of 50 ml. The number of PCR
cycles and annealing conditions for the primers have been
described elsewhere,12,19 except for IL-12p40 (38 cycles, an-
nealing at 62°C) and TNF-b/LT (35 cycles, annealing at 63°C).
Before cytokine PCR analysis, the cDNA concentration of all
samples was normalized to yield equivalent amounts of b-actin
PCR product. Differences in the yield of b-actin PCR product
were determined using an ImageMaster (Pharmacia Biotech,
Uppsala, Sweden). A total of 28 samples (consisting of 1 nor-
mal button, 6 grafts of untreated and 6 grafts of clodronate–
LIP–treated rats, as well as 1 normal rim, 7 rims of untreated,
and 7 rims of clodronate–LIP–treated rats), with a low b-actin
cDNA concentration were not used for further cytokine anal-
ysis. Subsequently, each cytokine PCR included all normalized
samples of each group, as well as a titration (1/20, 1/100,
1/500) of positive control cDNA from lipopolysaccharide-,
phorbol myristate acetate–, or Con A/IL-2–stimulated rat
spleen cells, and a negative control, which consisted of all
reagents, but without template DNA.
PCR products were analyzed by 2% agarose gel electro-
phoresis and ethidium bromide staining. For verification of
their identity, PCR products were transferred to Genescreen-
plus membranes (NEN–Du Pont, ‘s Hertogenbosch, the Neth-
erlands), and the filters were hybridized with specific oligonu-
cleotide probes. Internal control probes were labeled at the 59
end with [g-32P]ATP, using T4 polynucleotide kinase (New
England Biolabs, Beverly, MA). Hybridization was carried out in
63 SSC, 0.1% sodium dodecyl sulfate (SDS), 53 Denhardt’s and
100 mg/ml sheared denatured herring sperm DNA, and 20
pmol of labeled probe overnight at 65°C. Hybridized mem-
branes were washed with 23 SSC, 0.1% SDS at 65°C, and
exposed to x-ray film.
RESULTS
Clinical Features of Corneal Grafting
Corneal transplantation caused neovascularization and changes
in opacity with similar kinetics as previously described.4,12
Mild opacity (grade 1–2) was observed in some grafts of both
groups on POD 2, probably due to an acute inflammatory
reaction by surgical trauma. In the untreated group, opacity
decreased after POD 2, and corneas remained clear until the
time of rejection. In the clodronate–LIP–treated group, mild
opacity (grade 1–2) was observed during the period of subcon-
junctival injections, but corneas regained transparency after
POD 8. Corneal rejection was observed in all untreated rats
within 12 days (Fig. 1). A mean graft survival time of 10.9 days
was calculated using the Kaplan–Meier test. Maximal opacity
(grades 3–4) was observed at the onset of rejection (Fig. 2). In
contrast, graft rejection was not detected in the clodronate–
LIP–treated group up to POD 100. In untreated rats, neovas-
cularization progressed in time and reached grade 10 at POD
17. In most clodronate–LIP–treated rats, ingrowth of a few
vessels in the recipient cornea up to the sutures was observed.
Cytokine Expression in Corneas of Normal and
Grafted Rats
Cytokine mRNA levels in corneal tissues of normal and
transplanted rats were analyzed using RT–PCR. This method
is able to demonstrate differences in mRNA levels in a
semiquantitative manner.19 All samples were normalized for
b-actin mRNA content. Results of Southern blot analysis
with cytokines expressed in corneal grafts and rims are
shown in Figures 3 and 4, respectively. The cytokine expres-
sion pattern in normal and untreated rats was very similar to
the results of our previous study.12 Corneas of normal rats
TABLE 1. DNA Sequences of IL-12p40 and TNF-b/LT Oligonucleotide PCR Primers
and Control Probes







FIGURE 1. Survival of corneal grafts in untreated rats (–z z–) and clo-
dronate-LIP-treated rats (——) of which corneal mRNA was included in
the RT–PCR analysis. The mean graft survival time in untreated rats was
10.9 days.
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constitutively expressed IL-1RA, and some animals (1/3)
showed a strong signal for MIP-2, whereas all other cyto-
kines investigated were undetectable.
IL-1b mRNA Expression
Albeit weakly, IL-1b was detected from PODs 3 to 17 in 9 of 14
grafts and from PODs 3 to 12 in 6 of 10 rims of untreated rats.
IL-1b was not detected in grafts of liposome-treated rats but
was found in rims of these animals at POD 3 (in 2 of 3 samples)
and POD 100 (in 1 of 2 samples).
IL-1RA mRNA Expression
As in our previous study,12 IL-1RA mRNA was detected in
normal corneas. After transplantation, IL-1RA mRNA was de-
tected in almost all samples (13 of 14 grafts and 13 of 13 rims)
of untreated rats. IL-1RA mRNA levels were slightly increased at
POD 12 in grafts and rims. Despite constitutive expression,
clodronate–LIP treatment strongly decreased IL-1RA mRNA lev-
els in grafts, but not in rims, early after transplantation. In
grafts, IL-1RA mRNA levels returned to normal at POD 17 (in 2
of 4 samples) and POD 100 (in 2 of 2 samples).
IL-2 mRNA Expression
Interleukin-2 mRNA was detected from PODs 7 to 17 in 8 of 10
grafts and 9 of 10 rims of untreated rats. Clodronate–LIP treat-
ment completely abrogated the induced expression of IL-2 in
grafts and rims.
IL-4 mRNA Expression
Interleukin-4 mRNA was observed at PODs 7 and 12 in 3 of 6
grafts and from PODs 7 to 17 in 8 of 10 rims of untreated rats.
As for IL-2, IL-4 mRNA was absent in grafts and rims of clodr-
onate–LIP–treated rats.
IL-6 mRNA Expression
Interleukin-6 mRNA was detected from PODs 3 to 17 after
transplantation in all 14 grafts and 13 rims of untreated rats.
Interleukin-6 mRNA levels in grafts and corneal rims were
steady over time. The induction of IL-6 expression was strongly
reduced in clodronate-treated rats from PODs 7 to 17; IL-6 was
found only in grafts at POD 3 (in 2 of 4 samples) and POD 7 (in
1 of 3 samples) and in rims at POD 3 (in 2 of 3 samples).
Interleukin-6 mRNA was not detected in long-term grafts (POD
100).
IL-10 mRNA Expression
Similar to IL-6, IL-10 mRNA was detected from PODs 3 to 17
after transplantation in all 14 grafts and in 12 of 13 rims of
untreated rats. The highest level of IL-10 mRNA was detected
on POD 12. Clodronate–LIP treatment decreased IL-10 mRNA
expression in grafts, but IL-10 was detected from PODs 3 to
100 in 10 of 16 samples. Clodronate–LIP did not affect IL-10
mRNA expression in peripheral rims; it was detected from
PODs 3 to 17 in 10 of 13 samples as well as at POD 100 (in 2
of 2 samples).
IL-12p40 mRNA Expression
Like IL-6 and IL-10, IL-12p40 mRNA was present from PODs 3
to 17 in 13 of 14 grafts and in 11 of 13 corneal rims of untreated
rats. Clodronate–LIP treatment caused a transient increase in
IL-12p40 expression in grafts at POD 3 but did not affect mRNA
levels at later time points (PODs 7 to 17). Interleukin-12p40
mRNA was detected from PODs 3 to 17 in 12 of 14 grafts, as
well as in the two long-term grafts (POD 100). Interleukin-
12p40 mRNA was detected in all 15 rims of clodronate-treated
at similar levels compared with untreated rats.
IFN-g mRNA Expression
In grafts of untreated rats, a minor expression of IFN-g mRNA
was detected at POD 3 in 1 of 4 samples. A strong IFN-g signal
was detected from PODs 7 to 17 in 9 of 10 grafts and in 8 of 10
corneal rims. Clodronate–LIP treatment markedly decreased
IFN-g expression in grafts and rims; mRNA was detected in
none of the grafts and only at POD 12 in 1 of 3 rims tested.
TNF-a mRNA Expression
In untreated rats, TNF-a mRNA was detected from PODs 7 to
17 in 7 of 10 grafts and from PODs 3 to 17 in 10 of 13 rims. The
highest mRNA levels were found on POD 17. Clodronate–LIP
induced an increase in TNF-a mRNA levels in grafts and rims
early (PODs 3 and 7) after allograft transplantation. At POD
100, all animals showed a strong signal for TNF-a mRNA.
TNF-b/LT mRNA Expression
TNF-b/LT mRNA was detected at PODs 12 and 17 in 6 of 7
grafts and at slightly lower levels in all 6 rims of untreated rats.
FIGURE 2. A representative clinical appearance of a grafted cornea of
an untreated rat at the onset of rejection (POD 12) with an opacity
score of 4 and neovascularization score of 10 (A) and of a clodronate–
LIP–treated rat (at POD 35) with an opacity score of 0 and neovascu-
larization score of 4 (B).
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Similar to IL-2, IL-4, and IFN-g, liposome treatment completely
blocked TNF-b/LT mRNA expression in grafts. In rims of clo-
dronate–LIP–treated rats, however, TNF-b/LT mRNA was
readily detected from PODs 7 to 17 in 3 of 10 samples. At POD
100, a faint signal for TNF-b/LT was found in 1 of 2 rims of
clodronate-treated rats.
MCP-1 mRNA Expression
Like IL-6, MCP-1 mRNA was detected at similar levels from
PODs 3 to 17 in all 14 grafts and 13 rims of untreated rats.
Expression of MCP-1 was decreased in grafts from PODs 7 to 17
but not in rims of clodronate–LIP–treated rats. In these rats,
MCP-1 was found from PODs 3 to 17 in 12 of 14 grafts and in
all 13 rims, as well as on POD 100 in all samples.
MIP-2 mRNA Expression
In agreement with our previous studies,12,19 a variable expres-
sion of MIP-2 mRNA was found in normal corneas. After trans-
plantation, MIP-2 mRNA was detected from PODs 3 to 17 in all
14 grafts and 13 rims of untreated rats. Clodronate–LIP com-
pletely blocked the induced MIP-2 mRNA expression in 8 of 14
grafts from PODs 3 to 17, but did not alter the expression in
the grafts of the other 6 rats. MIP-2 mRNA was detected from
PODs 3 to 17 in all 13 rims of liposome-treated rats, at levels
slightly above those of untreated rats. A strong signal for MIP-2
was also found in the two long-term accepted grafts (at POD
100).
DISCUSSION
The results presented here demonstrate that prevention of
corneal allograft rejection by subconjunctival clodronate–LIP
treatment is associated with a marked alteration of the cytokine
mRNA expression profile in the allograft and surrounding re-
cipient cornea. mRNA levels of all cytokines investigated were
increased during allograft rejection compared with levels in
normal controls. Clodronate–LIP treatment caused a strong
decrease of IL-1b, IL-1RA, IL-2, IL-4, IL-6, IL-10, IFN-g, TNF-b/
LT, MCP-1, and MIP-2 mRNA levels in grafts and IL-1b, IL-2,
IL-4, IL-6, and IFN-g mRNA levels in corneal rims. In contrast,
TNF-a mRNA levels in grafts and rims were increased by
clodronate–LIP early after transplantation. Clodronate–LIP did
not alter IL-12p40 mRNA levels, except for a transient increase
in grafts at POD 3. Despite a normal appearance, on clinical
grounds, long-term corneal grafts still showed detectable
mRNA for IL-10, IL-12p40, TNF-a, and MCP-1, which were not
detected in any of the normal control corneas. MIP-2 mRNA,
which was occasionally present in normal corneas, also
showed a strong signal in long-term accepted grafts. The pro-
longed cytokine expression in these corneas may have been
triggered by the graft, by the sutures that were still present, or
by a long-lasting effect of the clodronate injections. Experi-
ments evaluating cytokine expression in normal rats treated
subconjunctivally with clodronate and longitudinal studies in
rats receiving an autograft could resolve this issue.
FIGURE 3. Cytokine mRNA expression in central corneal buttons of normal rats (N) and grafts of untreated and clodronate–liposome–treated rats
after transplantation. RT–PCR analysis was performed on corneal tissue harvested at different PODs after surgery. Each PCR included a negative
control (all reagents, but without cDNA template) and positive controls (a 1/20, 1/100, 1/500 dilution of spleen cDNA).
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The pattern of cytokine expression in corneas of un-
treated rats, which rejected the allograft by POD 12, was
largely consistent with the results of our previous study,12
except that expression of IL-2, IL-4, and IFN-g was detected at
an earlier time in the present study. This suggests that the
rejection process was slightly accelerated in the present study.
The reason for the discrepancy between these results is un-
known but may be related to improved surgical procedures or
to differences between batches of rats. The observed expres-
sion of IL-2, IL-4, IFN-g, and TNF-b/LT during allograft rejection
is compatible with the cytokine expression pattern of T helper
0 (Th0) cells, or of a combination of Th1 cells (which produce
IL-2, IFN-g, and TNF-b/LT) and Th2 cells, which produce
IL-4.20 This suggests that corneal graft rejection in this model is
driven either by Th0 cells or by a mixture of Th1 and Th2 cells.
Our results are in agreement with a recent study of Sano
et al.,14 who demonstrated by enzyme-linked immunosorbent
assay and immunohistochemistry that IL-1a, IL-2, TNF-a, and
IFN-g protein levels in the cornea were increased during graft
rejection. The latter results further imply that increased cyto-
kine mRNA expression in the cornea, as we have found, results
in increased cytokine protein levels.
Van der Veen et al.4 showed that local administration of
clodronate–LIP strongly reduced the number of macrophages
and T cells in the graft and recipient cornea. The almost
complete abrogation of IL-1b, IL-2, IL-4, IL-6, IFN-g, and TNF-
b/LT mRNA expression in allografts by clodronate–LIP sug-
gests that during rejection these cytokines are derived from
macrophages and T cells. The presence of IFN-g and TNF-b/LT
mRNA in a number of rims, but not grafts, of clodronate-treated
rats can be explained by differences in T-cell infiltration of
these sites.4 Macrophages are able to produce a variety of
cytokines and are likely a source of IL-1b and IL-6 in the cornea
in this model. A marked reduction of IL-1b and IL-6 expression
by clodronate–LIP–mediated depletion of macrophages has
been found in several studies.21–23 The fact that mRNA levels
of other macrophage-derived cytokines (TNF-a, IL-10, IL-12,
MCP-1, and MIP-2) were not completely reduced may be re-
lated to higher mRNA levels for these cytokines or to a higher
sensitivity of the PCR for these factors. Alternatively, these
cytokines could be produced by clodronate—LIP–resistant
macrophages,23 or by other (resident) cells in the cornea.12,24
The reduction in the mRNA levels of these cytokines after
clodronate treatment may result indirectly from the lack of
IL-1b and IL-6.
Surprisingly, clodronate–LIP induced a transient increase
in the levels of TNF-a and IL-12p40 mRNA in grafts, but not of
other macrophage-derived cytokines, early after transplanta-
tion. Moreover, TNF-a and IL-12p40 mRNA levels in rims from
PODs 3 to 100 were steady over time and not markedly altered
by clodronate, which was injected in the adjacent conjunctiva.
Together, these results suggest that TNF-a and IL-12p40 were
FIGURE 4. Cytokine mRNA expression in peripheral corneal rims of normal rats (N) and untreated and clodronate–liposome–treated rats after
allograft transplantation. RT–PCR analysis was performed on corneal tissue harvested at different PODs after surgery. Each PCR included a negative
control (all reagents without cDNA template) and positive controls (a 1/20, 1/100, 1/500 dilution of spleen cDNA).
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not produced by macrophages. Activated dendritic cells are
another source of TNF-a and IL-12.25,26 Dendritic cells (i.e.,
Langerhans cells), which are present in low numbers in the
peripheral cornea normally and in the central cornea after
transplantation,27–29 may be triggered to produce TNF-a and
IL-12p40 after activation by sutures or by the massive destruc-
tion of macrophages in clodronate–LIP–treated rats. Because of
their limited phagocytic activity,30 dendritic cells are presum-
ably not eliminated by clodronate–liposomes. Currently, we
are investigating the fate of local dendritic cells in this model.
Interleukin-1RA is constitutively produced in rat and hu-
man corneas.12,19,31,32 In the latter, IL-1RA is expressed mainly
by epithelial cells.31,32 The presence of IL-1RA in the cornea
implies the existence of an inherent control mechanism for
IL-1–mediated responses. Recently, Dana et al.33 found that
IL-1RA strongly reduced centripetal Langerhans cell migration
in the cornea. Interleukin-1RA mRNA expression was not mark-
edly decreased in untreated corneal allografts and autografts.12
However, IL-1RA mRNA expression in grafts, but not in the
recipient corneas, of clodronate-treated rats was completely
abolished immediately after transplantation. Interleukin-1RA
mRNA levels returned to normal by POD 17. Although the
epithelial cell layer on the graft of these rats appeared normal
early after transplantation (Ref. 4, P. Torres, personal observa-
tion), this finding suggests that clodronate may affect the nor-
mal activity of epithelial cells on the graft.
Our study clearly reveals that prolonged expression of
IL-10, IL-12p40, TNF-a, MCP-1, and MIP-2 in corneal grafts is
not correlated with rejection. This is consistent with our pre-
vious study, in which we showed IL-10, MCP-1, and MIP-2
mRNA expression in nonrejected autografts.12 It has been
hypothesized that IL-10 may contribute to graft survival by
blocking cytokine production and downregulating MHC class
II expression.34 Several studies showed that topical treatment
with IL-10 reduced corneal inflammation after herpes simplex
virus infection.35,36 However, local treatment with IL-10 during
corneal transplantation did not prolong allograft survival.37
Although TNF-a, MCP-1, and MIP-2 are considered to be in-
flammatory mediators,19 and IL-12 a pivotal factor in the devel-
opment of Th1 responses,38 their role in graft rejection re-
mains largely unknown. A number of studies have indicated
that IL-12 and TNF-a may have a beneficial role in graft accep-
tance. Interleukin-12 expression was found in long-term car-
diac allografts after rapamycin treatment.39 Moreover, IL-12
antagonism, by antibodies or an IL-12p40 homodimer receptor
antagonist, exacerbated cardiac allograft rejection.40 Interest-
ingly, Voest et al.41 have reported that IL-12 is capable of
blocking corneal neovascularization. In view of this activity,
expression of IL-12 in the cornea after transplantation may
serve to limit angiogenesis. With regard to TNF, it has been
shown that systemic administration of this cytokine decreased
skin allograft rejection.42 This tolerogenic effect may result
from a strong inhibition of the antigen presenting capacity of
dendritic cells by TNF.43
In summary, clodronate–LIP treatment markedly altered
the cytokine mRNA expression profile in corneal allografts of
rats. Whether the absence or the long-term presence of certain
cytokines in the cornea is necessary to acquire definite graft
acceptance remains to be clarified.
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